Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
European Medicines Agency announces a review of aliskiren-containing medicines
Notice type:
3rd Party Publications
Date:
23/12/2011
Product name or type:
Rasilamlo, Rasilez, Rasilez HCT, Rasitrio, Riprazo, Riprazo HCT, Sprimeo, Sprimeo HCT
Problem Or Issue:
The European Medicines Agency has started a review of aliskiren-containing medicines following termination of ALTITUDE study and has provided interim advice while review is ongoing.
Background Information Or Related Documents:
European Medicines Agency announces a review of aliskiren-containing medicines Document
Further Information:
European Medicines Agency - press release
« Back
Date Printed: 09/05/2024